[Multiple sclerosis: beyong first line therapies].
We are currently experiencing a key period in the management of patients with relapsing remitting multiple sclerosis. The application of new criteria allows early diagnosis, thus at a stage when the available immune treatments are the most likely to show a good efficacy. The therapeutic offer is expanding but its complexity too. It is thus important, for a given patient, to assess as precisely as possible the degree of severity of his/her disease, in order to give the drug with the optimal risk/benefit ratio.
Service de neurologie, Département des neurosciences cliniques, CHUV, 1011 Lausanne. myriam.schluep@chuv.ch
Myriam
M
Schluep
Renaud
R
Du Pasquier
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002755:Choice Behavior; D003131:Combined Modality Therapy; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000628:therapy*; D000069442:Natalizumab; D010353:Patient Education as Topic; D011409:Propylene Glycols / Q000627:therapeutic use; D013110:Sphingosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D035703:Therapies, Investigational / Q000379:methods / Q000706:statistics & numerical data
D000276:Adjuvants, Immunologic; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine